Vaping More Effective Than Nicotine Gum and Lozenges for Smoking Cessation in Disadvantaged Groups
A new study shows vaporized nicotine products outperform nicotine gum and lozenges in helping socially disadvantaged groups quit smoking, offering a promising harm reduction strategy.
Recent research highlights that vaporized nicotine products (VNPs), commonly known as e-cigarettes, demonstrate superior effectiveness in aiding smoking cessation compared to traditional nicotine replacement therapies (NRTs) like gum and lozenges. A comprehensive randomized controlled trial (RCT) conducted among individuals experiencing social disadvantages tested the efficacy of VNPs versus NRTs over a period of eight weeks.
The study involved 1,045 participants in New South Wales, Australia, all of whom smoked daily, were aged at least 18, willing to quit within two weeks, and received a government pension or allowance, indicating low socioeconomic status (SES). Participants were randomly assigned to either the VNP or NRT group, with the NRT group choosing between nicotine gum or lozenges, and the VNP group receiving nicotine e-liquid for use in various devices, available in flavors like tobacco, menthol, and fruit.
All participants received behavioral support through automated text messaging for five weeks. The primary outcome measured was six-month continuous abstinence from smoking. Results showed a significant difference: 28.4% of VNP users remained smoke-free after six months, compared to only 9.6% in the NRT group.
Subgroup analyses divided by age, gender, nicotine dependence, and mental health status confirmed VNPs' greater effectiveness across diverse demographic groups. This evidence suggests that VNPs could play a critical role in helping populations most impacted by smoking-related harms to achieve long-term abstinence.
The findings, published in the Annals of Internal Medicine, point towards the potential of vaporized nicotine products not only for the general population but especially for those with socioeconomic disadvantages, who often face hurdles in quitting smoking due to limited access to traditional therapies. This research underscores the importance of integrating innovative harm reduction strategies like VNPs into public health initiatives to reduce smoking prevalence and health disparities.
Source: https://medicalxpress.com/news/2025-07-vapes-effective-cessation-nicotine-gum.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Disrupted Gut Metabolism in Chronic Inflammatory Bowel Diseases: New Insights
Recent study reveals how chronic inflammatory bowel diseases severely disrupt gut metabolism and microbiome interactions, paving the way for personalized metabolic therapies.
Key Differences in STING Inhibition Between Humans and Mice Uncovered by Researchers
A groundbreaking study uncovers key differences in the STING pathway between humans and mice, influencing future drug development for immune-related therapies. Read about how these discoveries could shape treatments for cancer, neurodegeneration, and autoimmune diseases.
Innovative Treatment Design Software Creates Personalized Plans for Movement Impairments
A groundbreaking treatment design software from Rice University creates personalized neuromusculoskeletal models to optimize interventions for movement impairments, promising better outcomes and tailored therapies.
Study Links Social Media Posts about E-cigarettes and Cannabis to Increased Teen Substance Use
Recent research links exposure to social media posts about e-cigarettes and cannabis with increased likelihood of teen initiation and use, emphasizing the need for stricter platform regulations.